These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1360759)

  • 1. Pretreatment of the host cell with 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) is sufficient for its antiviral effect.
    Otová B; Votruba I; Holý A
    Acta Virol; 1992 May; 36(3):313-9. PubMed ID: 1360759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro.
    Neyts J; Snoeck R; Balzarini J; De Clercq E
    Antiviral Res; 1991 Jul; 16(1):41-52. PubMed ID: 1663729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
    Neyts J; De Clercq E
    Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.
    Stals FS; de Clercq E; Bruggeman CA
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2262-6. PubMed ID: 1666493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).
    Neyts J; Snoeck R; Schols D; Balzarini J; De Clercq E
    Virology; 1990 Nov; 179(1):41-50. PubMed ID: 2171213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system.
    Moore MR; Hamzeh FM; Lee FE; Lietman PS
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2404-8. PubMed ID: 7840578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
    Li SB; Yang ZH; Feng JS; Fong CK; Lucia HL; Hsiung GD
    Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
    Aduma P; Connelly MC; Srinivas RV; Fridland A
    Mol Pharmacol; 1995 Apr; 47(4):816-22. PubMed ID: 7723743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiviral effect of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine on adenovirus].
    Nakajima H; Goto M; Shimada Y; Nagamoto Y; Ishiko H; Inagawa W; Itoh N; Uchio E; Ohno S; Aoki K
    Nippon Ganka Gakkai Zasshi; 2000 Feb; 104(2):77-81. PubMed ID: 10714154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
    De Clercq E
    Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication.
    Snoeck R; Sakuma T; De Clercq E; Rosenberg I; Holy A
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1839-44. PubMed ID: 2854454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
    Cihlar T; Fuller MD; Mulato AS; Cherrington JM
    Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes.
    Srinivas RV; Connely M; Fridland A
    Antiviral Res; 1997 Jun; 35(1):23-7. PubMed ID: 9224958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir.
    Gordon YJ; Araullo-Cruz TP; Johnson YF; Romanowski EG; Kinchington PR
    Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2774-8. PubMed ID: 8977495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine on the replication and morphogenesis of herpes simplex virus type 1.
    Chatterjee S; Burns P; Whitley RJ; Kern ER
    Antiviral Res; 1992 Sep; 19(3):181-92. PubMed ID: 1332603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.
    Andrei G; Snoeck R; Piette J; Delvenne P; De Clercq E
    Oncol Res; 1998; 10(10):523-31. PubMed ID: 10338155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors.
    Bedard J; May S; Barbeau D; Yuen L; Rando RF; Bowlin TL
    Antiviral Res; 1999 Feb; 41(1):35-43. PubMed ID: 10321577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model.
    Gordon YJ; Romanowski EG; Araullo-Cruz T
    Invest Ophthalmol Vis Sci; 1994 Nov; 35(12):4135-43. PubMed ID: 7960596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs.
    Bravo FJ; Stanberry LR; Kier AB; Vogt PE; Kern ER
    Antiviral Res; 1993 May; 21(1):59-72. PubMed ID: 8391249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice.
    Neyts J; De Clercq E
    J Med Virol; 1993 Nov; 41(3):242-6. PubMed ID: 8263505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.